Article Sidebar
Views PDF: 4
EVALUATION OF LIVER FIBROSIS IMPROVEMENT IN CHRONIC HEPATITIS C PATIENTS WITH CIRRHOSIS TREATED WITH THE SOFOSBUVIR/VELPATASVIR/RIBAVIRIN REGIMEN
Main Article Content
Abstract
Hepatitis C has emerged as a significant global health concern. If left untreated, it can progress to cirrhosis and liver cancer, ultimately leading to fatal outcomes.
Objectives: To evaluate the improvement in cirrhosis among patients with chronic hepatitis C and cirrhosis treated with the sofosbuvir/velpatasvir and ribavirin regimen.
Subjects and methods: A cross-sectional descriptive study with longitudinal follow-up was conducted, with assessments performed 12 weeks after the completion of treatment. Ninety-three patients were diagnosed with chronic hepatitis C based on the Guidelines for the Diagnosis and Treatment of Viral
Hepatitis C, issued on April 29, 2021, under Decision 2065 of the Ministry of Health. These patients were treated with the sofosbuvir/velpatasvir and ribavirin regimen for 12 or 24 weeks and monitored for six months following treatment initiation.
Results: The median Fibroscan index value before treatment was 30.8 kPa (IQR: 20.9 - 45.0). After 12 weeks of treatment, this value decreased to 20.6 kPa (IQR: 10.7 - 28.0), with statistical significance (p < 0.05). The APRI scores at baseline (T0), week 4 (T4), week 12 (T12), and week 24 (T24) were 2.1, 0.6, 0.5, and 0.7, respectively. Significant differences in APRI scores were observed between T0 and T4, T0 and T12, and T0 and T24 (p < 0.05).
Conclusion: This study demonstrates that the oral combination regimen of sofosbuvir/velpatasvir and ribavirin significantly improves liver fibrosis in patients with chronic hepatitis C and cirrhosis
Article Details
Keywords
Chronic hepatitis C, cirrhosis, sofosbuvir/velpatasvir, ribavirin
References
2. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. Apr 2013;57(4):1333-42.doi:10.1002/hep.26141,http://www.ncbi.nlm.nih.gov/pubmed/23172780.
3. GBD. Mortality-Causes-of-Death-Collaborators. Global, regional, and national age-sex specific allcause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. . Lancet Jan 10 2015 2016;385(9963):117-71. . doi:10.1016/S0140-6736(14)61682-2.
4. Bộ Y tế. Quyết định 2065 về việc ban hành cập nhật mới về hướng dẫn chẩn đoán, điều trị bệnh viêm gan virus C (29/04/2021). 2021.
5. Curry MP OLJ, Bzowej N, et al,. Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N Engl J Med Dec 31 2015 2015;373(27):2618-28. doi:10.1056/NEJMoa1512614.
6. Takehara T SN, Nishiguchi S, et al,. Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial. . Journal of gastroenterology Jan 2019 2019;54(1):87-95. doi:10.1007/s00535-018-1503-x.
7. Tarik Asselah SB, Stephen Pianko et al. Sofosbuvir/velpatasvir in patients with hepatitis C virus genotype 1-6 and compensated cirrhosis or advanced fibrosis. Liver international : official journal of the International Association for the Study of the Liver. 2018;38:443-450. https://doi.org/10.1111/liv.13534.
8. Ngô Anh Thế và cộng sự. Tiến triển xơ hóa gan theo kết quả Fibroscan ở bệnh nhân viêm gan virus C mạn tính điều trị bằng thuốc kháng virus. Tạp chí Truyền nhiễm Việt Nam 2016; Số đặc biệt:38-41.
9. Vũ Thị Thu Hương và cộng sự. Hiệu quả điều trị phác đồ Peg-interferon + ribavirin + sofosbuvir trên bệnh nhân viêm gan virus C mạn tính tại Bệnh viện Bệnh Nhiệt đới Trung ương. Tạp chí Truyền nhiễm Việt Nam 2016; Số đặc biệt(1):33-37.